All In Biotech

Drug Trial Radar · NCT06103513

Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children

A Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children With Growth Hormone Deficiency in the First Year of Treatment

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Dec 10, 2023

Primary completion

Jan 5, 2028

Study completion Jan 5, 2028

Sponsor

Lead sponsor
Northwell HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 15 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A prospective, randomized, open-label single-blinded study of 50 subjects with growth hormone deficiency, ages 5 to 15 years in which 25 subjects will initiate rhGH therapy at 0.3mg/kg/week and the remaining 25 subjects will initiate their rhGH treatment at 0.2 mg/kg/week for the first 12 months of treatment. Safety parameters, height velocity, and adult height prediction by bone age determination will be assessed at 4-month intervals for 1 year following the initiation of rhGH therapy.

Conditions

  • Growth Disorders
  • Growth Failure
  • Growth Hormone Treatment
  • Growth

Interventions

  • SomatropinDrug

    The treatment of children with subcutaneous recombinant human growth hormone (rhGH) is the current gold standard of care for children with diagnosed GHD. This study will serve only to investigate the optimal dose of treatment in the first year of treatment with rhGH.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Growth Velocity (GV) in the first year after treatmentTime frame: I year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northwell Health

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.